Table 2.

Univariate and multivariate analyses of clinical parameters for the prediction of overall and progression-free survival

Clinical parameters	Overall survival				Progression-free survival
	Univariate analysis		Multivariate analysis		Univariate analysis		Multivariate analysis
	HR	P	Adjusted HR (95 % CI)	P	HR	P	Adjusted HR (95 % CI)	P
Age (year)
≦50	1.00		1.00		1.00		1.00
>50	1.09	0.540	1.08 (0.82–1.41)	0.598	1.10	0.436	1.08 (0.84–1.39)	0.543
Sex
Male	1.00		1.00		1.00		1.00
Female	0.93	0.634	1.06 (0.78–1.44)	0.695	0.97	0.844	1.02 (0.77–1.35)	0.889
Tumor location
Tibia/femur	1.00				1.00
Elsewhere	0.99	0.963			0.89	0.378
Pathological fracture
Yes	1.00				1.00
No	0.81	0.275			0.98	0.887
Tumor size					1.00
<8 cm	1.00				1.04	0.754
≥8 cm	1.09	0.524
ALP
Normal	1.00				1.00
Elevated	1.28	0.094			1.30	0.055
Clinical stagea
I–II	1.00		1.00		1.00		1.00
III	4.63	0.000	2.49 (1.66–3.72)	0.000	3.32	0.000	2.24 (1.59–3.15)	0.000
Metastasis at diagnosis
Absent	1.00		1.00		1.00		1.00
Present	5.09	0.000	2.43 (1.69–3.49)	0.000	3.42	0.000	1.72 (1.23–2.40)	0.002
Post-chemotherapy
Yes	1.00				1.00
No	1.02	0.865			1.05	0.687
NLR
Low NLR	1.00		1.00		1.00		1.00
High NLR	2.65	0.000	1.80 (1.35–2.41)	0.000	2.24	0.000	1.65 (1.26–2.15)	0.000
PLR
Low PLR	1.00		1.00		1.00		1.00
High PLR	1.84	0.000	1.27 (0.93–1.73)	0.136	1.57	0.001	1.17 (0.88–1.55)	0.273

ALP alkaline phosphatase, WBC white blood cell, NLR neutrophil-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio, HR hazard ratio, CI confidence interval

^aClinical stage according to Enneking surgical stage